Menopause and HRT — Physiology, Indications and Risk Assessment

Menopause is the permanent end of menstruation resulting from loss of ovarian follicular function. The clinical definition is retrospective: 12 months without menstruation, after excluding another explanation. It is a physiological reproductive transition rather than a diagnosis made from an isolated high hormone result. Pregnancy, medication effects and other causes of amenorrhoea still matter when the history is atypical.

Perimenopause is the transition during which menstrual cycles change and menopausal symptoms can develop. Ovarian activity fluctuates rather than stopping uniformly at the first hot flush. Irregular bleeding during this phase does not by itself prove permanent ovarian failure. Postmenopause describes the period after menopause has been established; new bleeding then needs a different clinical assessment.

The primary change is progressive depletion of ovarian follicles. Reduced granulosa-cell activity decreases production of oestradiol and inhibin, and anti-Müllerian hormone also declines. Less inhibitory feedback reaches the hypothalamic–pituitary axis, allowing FSH and LH to rise. The defining mechanism is ovarian loss of function with compensatory gonadotropin elevation, rather than pituitary failure.

The transition is not a perfectly smooth graph of falling oestrogen. Residual follicular activity can produce substantial fluctuation during perimenopause. Cycles may initially become shorter as the follicular phase shortens, then become longer and more often anovulatory. The eventual low-oestrogen state explains the established postmenopausal physiology, but a single perimenopausal measurement may be misleading.

For an examination question, the useful sequence is fewer follicles → less ovarian feedback → higher gonadotropins. Avoid replacing that mechanism with a memorized laboratory threshold. Thresholds and the role of testing depend on age, medication use and whether the clinical presentation is typical.

Vasomotor symptoms include hot flushes and night sweats. They reflect altered thermoregulation associated with hormonal change and can disrupt sleep and daily functioning. Mood symptoms, impaired concentration and sexual concerns may coexist, but their causes can be multifactorial. Do not attribute every new symptom in a midlife patient to menopause without considering another explanation.

Genitourinary syndrome of menopause includes vaginal dryness, irritation, discomfort with intercourse and urinary symptoms associated with oestrogen deficiency. These local symptoms may persist after vasomotor symptoms have improved. This distinction is clinically useful because treatment aimed at vaginal tissue may be appropriate even when there is no indication for systemic hormone therapy.

Oestrogen loss also contributes to increased bone turnover and loss of bone mass. Fracture risk depends on more than menopause alone, including prior fractures, age, mobility and other risk factors. The presence of menopause is therefore a reason to assess bone health appropriately, not a reason to prescribe the same drug to every postmenopausal patient.

• Link hot flushes and night sweats to vasomotor disturbance.
• Link vaginal dryness and dyspareunia to local tissue changes.
• Distinguish sleep disruption and mood symptoms from an automatic psychiatric diagnosis.
• Connect bone loss to fracture-risk assessment rather than to a universal treatment rule.

NICE recommends clinical identification in otherwise healthy people aged 45 or over who have a typical symptom pattern. Perimenopause is suggested by vasomotor symptoms and menstrual change. Menopause is suggested by the absence of periods for at least 12 months when hormonal contraception is not being used. Routine hormone panels add little in this typical setting.

FSH assessment is considered selectively in younger patients or when ovarian insufficiency is suspected. Premature ovarian insufficiency is considered in people under 40 with appropriate symptoms and menstrual disturbance. A separate evaluation is needed rather than simply labelling a young patient as having ordinary age-related menopause. Hormonal medication can also make laboratory and menstrual interpretation difficult.

• Ask about menstrual change, vasomotor symptoms, local symptoms and medication use.
• Determine whether hormonal contraception, hysterectomy or another intervention obscures the menstrual history.
• Consider pregnancy and alternative causes of amenorrhoea when relevant.
• Investigate atypical bleeding and other red flags separately.
• Use laboratory testing when the clinical context makes it informative, rather than reflexively in every patient.

For revision, separate a typical age-related transition from amenorrhoea at an unexpectedly young age. The first often needs clinical recognition and symptom management; the second may need investigation for ovarian insufficiency and its cause. New bleeding after established menopause should not be explained away as evidence that ovarian cycles have simply restarted.

Hormone replacement therapy, also called menopausal hormone therapy, is an effective treatment for bothersome vasomotor symptoms. Treatment should respond to the patient’s symptom burden and preferences, with individual assessment of benefits and risks. Menopause itself does not create an obligation to prescribe hormones, and a mildly symptomatic patient may reasonably choose supportive or nonhormonal approaches.

HRT also helps prevent bone loss while it is used, but deciding how to manage fracture risk requires a broader assessment. Do not frame HRT as a routine prescription for preventing every chronic disease after menopause. NICE explicitly advises against using combined or oestrogen-only HRT for primary or secondary cardiovascular prevention.

Premature ovarian insufficiency has a different balance of benefits and risks from starting hormone therapy much later after natural menopause. Replacement is commonly offered, unless contraindicated, to address symptoms and the consequences of early hormone deficiency. The treatment choice can include HRT or an appropriate hormonal contraceptive strategy, depending on clinical needs and preferences.

Systemic oestrogen stimulates the endometrium. If a patient has a uterus, unopposed systemic oestrogen increases the risk of endometrial hyperplasia and cancer. An appropriate progestogen regimen supplies endometrial protection. This is the central reason for combined therapy, and it should not be confused with the idea that progestogen is added simply to treat hot flushes.

After total hysterectomy, oestrogen-only HRT is generally appropriate because there is no endometrium to protect. Complex circumstances, such as a condition influenced by hormones or uncertainty about residual tissue, may need specialist advice. An examination answer should identify the usual uterus-based rule while avoiding an absolute claim that the patient’s other history can never change treatment.

Sequential and continuous regimens differ in the pattern of progestogen exposure and expected bleeding. Selection depends on the menopausal stage and treatment circumstances. Avoid inventing a single dose or cycle schedule for all preparations: the progestogen must provide protection appropriate to the oestrogen exposure.

Oral and transdermal oestrogen can treat systemic menopausal symptoms. Transdermal preparations deliver hormone through the skin and avoid the hepatic first-pass exposure of oral treatment. The route matters particularly when assessing thromboembolic risk; it does not remove the requirement for endometrial protection when systemic oestrogen is used with an intact uterus.

NICE distinguishes the routes for venous thromboembolism: oral HRT increases VTE risk, whereas the guidance does not identify an increased VTE risk with transdermal HRT. That route comparison does not mean a patch is suitable for every patient with a prior clot. Personal history, thrombophilia and other contraindications still require individual or specialist assessment.

For genitourinary symptoms, low-dose vaginal oestrogen has predominantly local action and much lower systemic exposure than systemic therapy. It can be used for local symptoms even when systemic HRT is unnecessary, and sometimes alongside systemic HRT if those symptoms persist. Local moisturizers and lubricants can also help according to the symptom and preference.

The practical examination contrast is a patient with generalized vasomotor symptoms versus one with isolated vaginal discomfort. Choose the treatment that reaches the relevant target and assess its risks. Escalating all local symptoms to systemic therapy unnecessarily obscures the route-based reasoning the question is testing.

Risk assessment depends on the person, hormone combination, route, dose, duration and timing. Combined HRT increases breast cancer risk, with duration and other features influencing the discussion. Oestrogen-only therapy has a different risk profile. Do not transfer the findings for a particular combination to every preparation or claim that all HRT is equally safe or equally harmful.

Important histories include oestrogen-sensitive malignancy, unexplained vaginal bleeding, venous thromboembolism, stroke and liver disease. These findings can make routine systemic prescribing inappropriate or require specialist assessment. Unexplained bleeding should be evaluated rather than masked by treatment. Guidance distinguishes systemic therapy from low-dose local vaginal treatment, whose risk assessment is different.

• Clarify the symptom benefit expected from treatment.
• Check uterus status and need for endometrial protection.
• Review personal and family history and relevant vascular or cancer risks.
• Choose route and formulation with those risks in mind.
• Discuss alternatives and review the decision over time.

Established coronary disease or stroke deserves a specialist, individualized discussion under NICE guidance rather than a simplistic claim that hormones prevent recurrence. Likewise, patients with a breast cancer history require careful consideration of nonhormonal and local options with the appropriate specialist team. The revision principle is to recognize the risk-bearing history before selecting treatment.

Use the lowest effective dose consistent with the treatment goal, and reassess benefits and adverse effects. NICE recommends review at 3 months and annually thereafter, with earlier review when clinically indicated. Treatment duration is individualized; neither an automatic stop date nor indefinite unreviewed continuation is an adequate general rule.

Follow-up focuses on symptom response, bleeding, tolerability and emerging risk factors. Routine FSH, oestradiol or progesterone testing is not used to titrate ordinary menopausal HRT to a laboratory target. New, persistent or concerning bleeding needs assessment according to the regimen and clinical context rather than being dismissed as harmless.

Menopause-specific cognitive behavioural therapy is an option for vasomotor symptoms, including alongside HRT or when HRT is unsuitable or declined. Other nonhormonal treatments may be considered according to the symptom and guideline context. Do not describe antidepressants or clonidine as routine first-line treatment for vasomotor symptoms alone when using NICE guidance.

• Menopause is a retrospective clinical diagnosis in the appropriate context.
• High gonadotropins reflect loss of ovarian feedback.
• Systemic oestrogen with a uterus requires endometrial protection.
• Local vaginal and systemic HRT are not interchangeable.
• HRT is used for appropriate symptom and replacement goals, not cardiovascular prevention.